Anti-human CXCR5 antibodies and uses thereof
JP2024509946A5Pending Publication Date: 2025-03-18HIFIBIO HONG KONG LTD
0 Cites 0 Cited by
Patent Information
- Application Number
- JP2023555391
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2021-08-05
- Filing Date
- 2022-03-09
- Publication Date
- 2025-03-18
AI Technical Summary
Technical Problem
Current treatments for Sjögren's syndrome and other diseases associated with CXCR5 overexpression, such as lymphoma and breast cancer, primarily target symptoms and do not address the underlying mechanism of CXCR5-mediated tissue damage and pathogenic antibody production.
Method used
Development of an antagonistic anti-hCXCR5 antibody that inhibits CXCR5 via antibody-dependent cell-mediated cytotoxicity (ADCC), selectively depleting CXCR5+ cells to reduce tissue damage and pathogenic antibody production.
Benefits of technology
The anti-hCXCR5 antibody effectively inhibits Tfh and B cell migration, reduces tissue damage, and decreases pathogenic antibody production, providing therapeutic benefits for Sjögren's syndrome and other CXCR5-related conditions.
✦ Generated by Eureka AI based on patent content.
Abstract
The present invention provides monoclonal antibodies and antigen-binding fragments thereof specific for (human) CXCR5, and methods of their use in the treatment (including combination therapy) of Sjogren's syndrome, certain cancers, and autoimmune diseases.
Need to check novelty before this filing date? Find Prior Art